3646 results for «722»
3646 results
An intrepid solution for transfemoral treatment of mitral regurgitation
21 Nov 2023 – From PCR London Valves 2023
In this session, get insights into the APOLLO EU trial and its current progress, obtain a comprehensive understanding of the latest data from the Early Feasibility TF trial, and discern which patients stand to benefit the most from this treatment.
TAVI - Alternative access - Part 1
19 Nov 2023 – From PCR London Valves 2023
Learn more about the evolving landscape of TAVI techniques and access options with this session: experience the first-hand application of JenaValve Trilogy via transaxillary access in treating aortic regurgitation, delve into the challenges and solutions of transcaval TAVI in a patient with right iliac vein occlusion,...
TAVI in bicuspid anatomy - Part 1
19 Nov 2023 – From PCR London Valves 2023
Delve into the complexities of TAVI within bicuspid anatomy through this selection of cases: encounter a challenging scenario with a bicuspid aortic valve, where the ejection fraction is -14%, coupled with left ventricle thrombus and an aortic valve calcium score reaching 11,000, learn more about the...
Tricuspid TEER - Part 1
19 Nov 2023 – From PCR London Valves 2023
Gain insights into Tricuspid Transcatheter Edge-to-Edge Repair (TEER) with this session: explore the congestion patterns observed in severe tricuspid regurgitation and gain a deeper understanding of transcatheter treatment modalities, delve into the baseline characteristics of the Tri.Fr randomized trial on treating tricuspid regurgitation, witness the application...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
